TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.
Pol Specenier(Antwerp University Hospital), Jan B. Vermorken(University of Antwerp), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Éva Remenár(National Institute of Oncology), Paul M. Clément(Universitair Ziekenhuis Leuven), Catherine Fortpied(European Organisation for Research and Treatment of Cancer), Ravi Karra Gurunath(European Organisation for Research and Treatment of Cancer), Dirk Schrijvers(ZNA Middelheim Hospital), Lisa Licitra(University of Milan), Jan Buter
Cited by 1
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994